CSSPF Stock Chart & Stats
$0.89
$0.00(0.00%)
At close: 4:00 PM EDT
$0.89
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.69 - $1.03
Previous CloseN/A
Volume60.00K
Average Volume (3M)0.00
Market Cap
$346.45M
Enterprise Value$259.54
Total Cash (Recent Filing)$19.90M
Total Debt (Recent Filing)$1.00M
Price to Earnings (P/E)37.3
Beta4.17
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.43%
Share Statistics
EPS (TTM)0.02
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)3.73
Price to Sales (P/S)5.65
P/FCF Ratio17.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$676.75K
Bulls Say, Bears Say
Bulls Say
Acquisition InterestNIOX has announced it has received a possible 81p/share all-cash offer from Keensight Capital valuing the business at £322m.
Market CompetitionThere also appear to be other counterparties considering an offer for the business so competing bids may yet emerge.
Shareholder ValueThe offer represents good value for shareholders for a single-product business in this space.
Bears Say
Acquisition UncertaintyDiscussions are early stages with no formal offer as yet from Keensight.
Macroeconomic EnvironmentKeensight Capital has announced that it does not intend to make a firm offer for the business at this stage due to the current uncertain macroeconomic environment.
Share Price VolatilityA level of weakness in the share price is anticipated due to recent newsflow and share price action related to it.
Circassia Pharmaceuticals News
CSSPF FAQ
What was Circassia Pharmaceuticals PLC’s price range in the past 12 months?
Circassia Pharmaceuticals PLC lowest stock price was $0.69 and its highest was $1.03 in the past 12 months.
What is Circassia Pharmaceuticals PLC’s market cap?
Circassia Pharmaceuticals PLC’s market cap is $346.45M.
When is Circassia Pharmaceuticals PLC’s upcoming earnings report date?
Circassia Pharmaceuticals PLC’s upcoming earnings report date is Sep 10, 2026 which is in 47 days.
How were Circassia Pharmaceuticals PLC’s earnings last quarter?
Circassia Pharmaceuticals PLC released its earnings results on Mar 24, 2026. The company reported $0.004 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Circassia Pharmaceuticals PLC overvalued?
According to Wall Street analysts Circassia Pharmaceuticals PLC’s price is currently Overvalued.
Does Circassia Pharmaceuticals PLC pay dividends?
Circassia Pharmaceuticals PLC pays a Annually dividend of $0.021 which represents an annual dividend yield of 2.43%. See more information on Circassia Pharmaceuticals PLC dividends here
What is Circassia Pharmaceuticals PLC’s EPS estimate?
Circassia Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Circassia Pharmaceuticals PLC have?
Currently, no data Available
What happened to Circassia Pharmaceuticals PLC’s price movement after its last earnings report?
Circassia Pharmaceuticals PLC reported an EPS of $0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.006%.
Which hedge fund is a major shareholder of Circassia Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in CSSPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Circassia Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.02%
12-Months-Change
Fundamentals
Return on Equity
2.43%
Trailing 12-Months
Asset Growth
11.40%
Trailing 12-Months
Company Description
Circassia Pharmaceuticals PLC
NIOX Group Plc is a worldwide company dedicated to innovating, developing, and distributing medical devices that measure fractional exhaled nitric oxide (FeNO). A key product is the NIOX VERO system, an easily portable and non-invasive diagnostic tool designed for immediate, on-site patient use. This system includes a compact device alongside a suite of disposable items like sensors, individual mouthpieces, and breathing handles, all essential for quantifying FeNO levels in patients. The company, which was founded in 2006 and is headquartered in Oxford, United Kingdom, was formerly known as Circassia Group Plc until its renaming to NIOX Group Plc in September 2022.
Technical Analysis
Allergy Therapeutics
―
Bioventix
―
EKF Diagnostics Holdings
―
Diaceutics
―
Abingdon Health PLC
―
Ownership Overview
2.14% Insiders
<0.01% Other Institutional Investors
97.42% Public Companies and
Individual Investors